Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04549363 · ClinicalTrials.gov registry record · Phase 3
Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
A Phase 3 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
NCT04549363 is a Phase 3 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 16 participants.
The verdict
NCT04549363, a Phase 3 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study will be available to any participant who has received or is currently receiving belantamab mafodotin treatment through either a clinical trial, an access program, or a physician prescription. Participants do not need to be on active treatment. The purpose of this study is to gain a more complete understanding of the pathophysiology of the corneal events seen in some participants with relapsed/refractory multiple myeloma (RRMM) treated with belantamab mafodotin. A superficial corneal epithelial tissue specimen will be obtained by performing impression cytology (IC) or superficial keratectomy (SK) procedure in participants treated with belantamab mafodotin. The procedure will only be performed in one eye, most affected by the corneal epithelial changes. This specimen will undergo pathologic examination and composition analysis.
Interventions
- DRUG Belantamab mafodotin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2020-12-21 |
| Est. Completion | 2022-11-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04549363
The ClinicalTrials.gov registry entry for NCT04549363 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Belantamab mafodotin is the first listed.
NCT04549363 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04549363 about?
NCT04549363 is a clinical study titled "Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin". This study will be available to any participant who has received or is currently receiving belantamab mafodotin treatment through either a clinical trial, an access program, or a physician prescription. Participants do not need to be on active treatment. The purpose of this study is to gain a more c...
What is the current status of trial NCT04549363?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2020-12-21. Estimated completion is 2022-11-21.
What interventions are being tested in trial NCT04549363?
The interventions under investigation include: Belantamab mafodotin (DRUG).
Who is sponsoring clinical trial NCT04549363?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.